PLUS1
2.88
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Hepion Pharmaceuticals Inc | HEPA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.04 | 1.41% | 2.88 | 2.76 | 2.9386 | 2.88 | 2.84 | 19:57:38 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.86 | 2.88 | 0.02 | 0.69% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,079 | 287,217 | $ 2.84 | $ 816,781 | 844,219 | 1.00 - 8.35 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:36:35 | formt | 100 | $ 2.88 | USD |
Hepion Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 25.99M | 9.03M | 9.02M | $ - | $ - | -15.29 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Hepion Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/30/2020 | 06:41 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 6/30/2020 | 06:36 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/25/2020 | 19:18 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/22/2020 | 16:55 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/15/2020 | 11:25 | Edgar (US Regulatory) | Amended Annual Report (10-k/a) |
| 6/15/2020 | 09:23 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/12/2020 | 16:48 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HEPA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.57 | 3.36 | 2.46 | 2.83 | 634,992 | 0.31 | 12.06% |
| 1 Month | 2.14 | 3.60 | 1.953 | 2.76 | 817,715 | 0.74 | 34.58% |
| 3 Months | 1.53 | 3.60 | 1.26 | 2.09 | 742,996 | 1.35 | 88.24% |
| 6 Months | 5.21 | 7.50 | 1.00 | 2.89 | 692,510 | -2.33 | -44.72% |
| 1 Year | 3.11 | 8.35 | 1.00 | 3.74 | 884,297 | -0.23 | -7.4% |
| 3 Years | 3.11 | 8.35 | 1.00 | 3.74 | 884,297 | -0.23 | -7.4% |
| 5 Years | 3.11 | 8.35 | 1.00 | 3.74 | 884,297 | -0.23 | -7.4% |
Hepion Pharmaceuticals Description
| Hepion Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. The company's cyclophilin inhibitor, CRV431 targets multiple biochemical pathways involved in the progression of liver disease. |
